About Bio-Reference Laboratories (NASDAQ:BRLI)
Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Industry, Sector and Symbol
Sub-IndustryHealth Care Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity12.67%
Return on Assets8.38%
Bio-Reference Laboratories (NASDAQ:BRLI) Frequently Asked Questions
What is Bio-Reference Laboratories' stock symbol?
Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."
How were Bio-Reference Laboratories' earnings last quarter?
Bio-Reference Laboratories Inc (NASDAQ:BRLI) issued its earnings results on Thursday, December, 18th. The medical research company reported $0.66 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.63 by $0.03. The medical research company earned $227.60 million during the quarter, compared to the consensus estimate of $228.81 million. Bio-Reference Laboratories had a return on equity of 12.67% and a net margin of 4.67%. The company's revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.40 earnings per share. View Bio-Reference Laboratories' Earnings History.
Who are some of Bio-Reference Laboratories' key competitors?
Some companies that are related to Bio-Reference Laboratories include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Bio-Reference Laboratories been receiving favorable news coverage?
News stories about BRLI stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bio-Reference Laboratories earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 45.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Bio-Reference Laboratories?
Shares of BRLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Bio-Reference Laboratories?
Bio-Reference Laboratories' mailing address is 481 Edward H Ross Dr, ELMWOOD PARK, NJ 07407-3118, United States. The medical research company can be reached via phone at +1-201-7912186.
MarketBeat Community Rating for Bio-Reference Laboratories (BRLI)MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe BRLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bio-Reference Laboratories (NASDAQ:BRLI) Analyst Ratings History
(Data available from 4/21/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Bio-Reference Laboratories (NASDAQ:BRLI) Earnings History and Estimates Chart
Bio-Reference Laboratories (NASDAQ BRLI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/8/2015||Q215||$0.46||$0.38||$227.33 million||$224.00 million||View||Listen|
|3/5/2015||Q115||$0.36||$0.24||$216.40 million||$209.00 million||View||Listen|
|12/18/2014||Q414||$0.63||$0.66||$228.81 million||$227.60 million||View||Listen|
|8/27/2014||Q314||$0.53||$0.55||$210.44 million||$222.10 million||View||Listen|
|6/5/2014||Q214||$0.32||$0.37||$0.1956 million||$201.30 million||View||Listen|
|3/4/2014||Q114||$0.14||$0.11||$175.52 million||$181.30 million||View||Listen|
|12/19/2013||Q4||$0.40||$0.40||$188.96 million||$192.20 million||View||Listen|
|8/29/2013||Q3 2013||$0.51||$0.53||$183.50 million||$185.40 million||View||Listen|
|6/6/2013||Q2 2013||$0.41||$0.41||$176.04 million||$176.50 million||View||Listen|
|2/28/2013||Q1 2013||$0.28||$0.31||$165.44 million||$161.30 million||View||Listen|
|8/30/2012||Q312||$0.43||$0.45||$0.1737 million||$0.1723 million||View||N/A|
|12/16/2010||$0.30||$0.31||$124.19 million||$126.60 million||View||N/A|
Bio-Reference Laboratories (NASDAQ:BRLI) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Bio-Reference Laboratories (NASDAQ BRLI) News Headlines
Bio-Reference Laboratories (NASDAQ:BRLI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bio-Reference Laboratories (NASDAQ:BRLI) Income Statement, Balance Sheet and Cash Flow Statement
Bio-Reference Laboratories (NASDAQ BRLI) Stock Chart for Saturday, April, 21, 2018